Literature DB >> 23913166

Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance.

Kien T Mai1, Trevor A Flood, Phillip Williams, Zuzana Kos, Eric C Belanger.   

Abstract

There are two pathways of urothelial carcinogenesis: low-grade urothelial carcinoma (LGUC) with low rates of gene alterations and high-grade urothelial carcinoma (HGUC) with numerous gene alterations. HGUC often displays strong reactivity for cytokeratin 20 (CK20) and p16. Despite distinct molecular changes, urothelial carcinoma (UC) with both low- and high-grade features is not uncommon. We examined cases with patterns of mixed low- and high-grade UC (MLHGUC). Consecutive cases of UC at our institution were reviewed. There were 45 cases that showed a mixture of both LGUC and HGUC. IHC for CK5, CK20, CD44, p16, and Ki67 was performed. Areas of HGUC displayed strong and diffuse reactivity for p16, CK20, and Ki67 in 20-50 % of the tumor, while LGUC areas had negative or focal reactivity for CK20 and Ki67 in 10-30 %. There were two distinct cohorts of MLHGUC: patients with a history of LGUC (group A) and those without (group B). Group A patients (n = 8) had a history of LGUC for 1-10 years. The tumor specimens weighed 1.5 ± 1.7 g and had HGUC components of 25 ± 20 % of the tissue. Superficial invasion was present in one case. All tumors had BCG treatment with one recurrence. In group B (n = 37), tumor specimens weighed 3 ± 3.9 g and had HGUC components in 43 ± 21 % of the tissue. Superficial invasion was present in five cases, and muscle invasion with lung metastasis occurred in one case. Four cases were refractory to BCG with an increased proportion of HGUC, and one case requiring cystectomy. Differences in size and proportion of HGUC between groups A and B MLHGUC were significant (P < 0.05), with group B presenting with a higher tumor burden and proportion of HGUC. MLHGUC is diagnostically challenging and is commonly assigned high grade since this determines prognosis. Group A MLHGUC likely develops as a result of progression from LGUC, whereas group B MLHGUC likely develops de novo, is associated with larger tumors, shows a higher proportion of HGUC, and follows a worse prognosis. Despite the similar histology of groups A and B, assignment to HGUC in a binary system may mask important prognostic information.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23913166     DOI: 10.1007/s00428-013-1456-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  33 in total

Review 1.  Review. Non-papillary urothelial lesions of the urinary bladder: morphological classification and immunohistochemical markers.

Authors:  Constantina D Petraki; Constantinos P Sfikas
Journal:  In Vivo       Date:  2008 Jul-Aug       Impact factor: 2.155

2.  Mutation of the 9q34 gene TSC1 in sporadic bladder cancer.

Authors:  N Hornigold; J Devlin; A M Davies; J S Aveyard; T Habuchi; M A Knowles
Journal:  Oncogene       Date:  1999-04-22       Impact factor: 9.867

3.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.

Authors:  C Billerey; D Chopin; M H Aubriot-Lorton; D Ricol; S Gil Diez de Medina; B Van Rhijn; M P Bralet; M A Lefrere-Belda; J B Lahaye; C C Abbou; J Bonaventure; E S Zafrani; T van der Kwast; J P Thiery; F Radvanyi
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

4.  Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.

Authors:  Allison Edgecombe; Bich N Nguyen; Bojana Djordjevic; Eric C Belanger; Kien T Mai
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-05

5.  Prognostic significance of a grading system considering tumor heterogeneity in muscle-invasive urothelial carcinoma of the urinary bladder.

Authors:  S Krüger; C Thorns; A Böhle; A C Feller
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

6.  Genetic alterations in bladder cancer.

Authors:  G Dalbagni; J Presti; V Reuter; W R Fair; C Cordon-Cardo
Journal:  Lancet       Date:  1993-08-21       Impact factor: 79.321

7.  Correlation between Apoptosis and Histological Grade of Transitional Cell Carcinoma of Urinary Bladder.

Authors:  Mohammadreza Jalalinadoushan; H Peivareh; A Azizzadeh Delshad
Journal:  Urol J       Date:  2004       Impact factor: 1.510

8.  Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up.

Authors:  Hui Yin; Anthony S Y Leong
Journal:  Am J Clin Pathol       Date:  2004-05       Impact factor: 2.493

9.  Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder.

Authors:  Kutsal Yorukoglu; Burcin Tuna; Emel Dikicioglu; Ender Duzcan; Aydin Isisag; Sait Sen; Ugur Mungan; Ziya Kirkali
Journal:  Virchows Arch       Date:  2003-10-08       Impact factor: 4.064

Review 10.  The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement?

Authors:  Jonathan I Epstein
Journal:  Crit Rev Oncol Hematol       Date:  2003-08       Impact factor: 6.312

View more
  5 in total

1.  Altered expression of CKs 14/20 is an early event in a rat model of multistep bladder carcinogenesis.

Authors:  Rui M Gil da Costa; Paula A Oliveira; Carmen Vasconcelos-Nóbrega; Regina Arantes-Rodrigues; Rosário Pinto-Leite; Aura A Colaço; Luis F de la Cruz; Carlos Lopes
Journal:  Int J Exp Pathol       Date:  2015-10-30       Impact factor: 1.925

2.  Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy.

Authors:  Tician Schnitzler; Nadina Ortiz-Brüchle; Ursula Schneider; Isabella Lurje; Karolina Guricova; Alexander Buchner; Gerald Bastian Schulz; Axel Heidenreich; Nadine Therese Gaisa; Ruth Knüchel; Stefan Garczyk
Journal:  Cell Oncol (Dordr)       Date:  2020-05-22       Impact factor: 6.730

3.  The Clinical Impact of Tumor Grade Heterogeneity in Non-muscle-invasive Urothelial Carcinoma of the Bladder.

Authors:  Meftun Culpan; Ferhat Keser; Ayberk Iplikci; Gozde Kir; Gokhan Atis; Asif Yildirim
Journal:  Medeni Med J       Date:  2021-12-19

4.  Characterizing the tumor microenvironment in rare renal cancer histological types.

Authors:  Naoise C Synnott; Maria Luana Poeta; Manuela Costantini; Ruth M Pfeiffer; Mengying Li; Yelena Golubeva; Scott Lawrence; Karun Mutreja; Carla Amoreo; Malgorzata Dabrowska; Giuseppe Simone; Edoardo Pescarmona; Petra Lenz; Mary Olanich; Maire Duggan; Mustapha Abubakar; Vito Michele Fazio; Michele Gallucci; Steno Sentinelli; Maria Teresa Landi
Journal:  J Pathol Clin Res       Date:  2021-10-07

5.  Evaluation of P53 and CK20 Immunohistochemical Markers in Comparison with Morphologic Findings in Low- and High-grade Urothelial Carcinomas.

Authors:  Mahsa Ahadi; Afshin Moradi; Banafshe Bayat; Hanieh Zham; Seyed Jalil Hosseini; Sara Zahedifar; Afsoon Taghavi
Journal:  Iran J Pathol       Date:  2021-05-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.